Approximately one-third of teens may be missing annual checkups according to data from the US Department of Health and Human Services and the US Census. Teens often encounter social, emotional, and physical issues that may include eating disorders and obesity, substance abuse, and sexually transmitted infections. While experts agree that teens should get annual medical checkups to be screened for health risks and discuss important health-related matters, perceptions exist that may contribute to millions of teens missing out on yearly visits. To better understand perceptions about teen health, the National Foundation for Infectious Diseases (NFID), in collaboration with, and with support from Pfizer Inc, conducted a national survey, fielded by Harris Interactive, of more than 2,000 parents of teens, teens, and healthcare professionals.
To view Multimedia News Release, go to http://www.multivu.com/players/English/60287-nfid-myteenhealth-survey/
When searching the pharmacy shelves, people looking for help to support healthy good cholesterol with a dietary supplement niacin may inaccurately associate the ingredient nicotinic acid with smoking cessation because it sounds like nicotine, warns leading cardiologist, Dr. Carl Lavie, Medical Director of Cardiac Rehabilitation and Prevention at the John Ochsner Heart and Vascular Institute, New Orleans, LA. In fact, nicotinic acid is the only form of dietary supplement niacin that is clinically proven to support good cholesterol, also known as high-density lipoprotein cholesterol, or HDL.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58806-upsher-smith-cardiologist-advice-niacin-nicotinic-acid-flush-free
SIRO Clinpharm, a leading full service clinical research organization, unveiled its new brand identity on Friday. The new look affirms the recent transformation in the company’s business strategy.
“With the vast experience garnered over the past 16 years, SIRO was set to take a leap forward. With its customer centric leadership, we have built depth in various areas of competencies, leveraging our 4 pillars – people, processes, technologies and solutions,” said Dr. Gautam Daftary, founder and chairman, SIRO Clinpharm.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58672-SIRO-Clinpharm-unveils-new-brand-identity
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE:CMN), and Prestige Ameritech, the only two major U.S.-based medical mask manufacturers have joined forces to bring attention to a glaring void in public health research and policy – that, if addressed, has the potential to more quickly provide a simple, effective tool to mitigate the spread of influenza and other respiratory borne viruses. The awareness campaign comes in response to a new study, “ Exposure to Influenza Virus Aerosols During Routine Patient Care,” published in The Journal of Infectious Diseases, showing that influenza viruses may spread as far as six feet from a person coughing or sneezing, and that some people, referred to as “super spreaders,” may be more likely to spread the virus. The study, supported by the Department of Health and Human Services with a $600,000 research grant, pointed specifically to concerns for healthcare workers being exposed to coughs from sick patients. Yet government research and policy continues to overlook face masks as a feasible protection measure for both the healthcare industry and the general public.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60417-cantel-medical-fitted-mask-infectious-disease-control-public-health-policy
Every 40 seconds a stroke occurs in the United States, according to the American Heart Association/American Stroke Association. To raise awareness about F.A.S.T. — an acronym to recognize and respond to the sudden warning signs of stroke, the American Heart Association/American Stroke Association and Ad Council are unveiling a new, national multimedia public service advertisement (PSA) campaign. F.A.S.T. is designed to help bystanders spot a stroke fast because the quicker a stroke victim receives medical attention, the greater his or her chances of survival and a better recovery. To view Multimedia News Release, go to http://www.multivu.com/mnr/58828-ad-council-american-stroke-association-stroke-awareness-f-a-s-t
OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional™ nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex® nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex® liquid nasal spray (20mg).
To view Multimedia News Release, go to http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
More than half (53 percent) of family members serving as primary caregivers for loved ones have lost income due to the demands of providing care. The study, Beyond Dollars: A Way Forward, also found that caregivers whose loved ones did not have long term care insurance face additional stresses including covering the cost of daily living, medical and other support-type needs.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54349-genworth-study-planning-reduces-stress-faced-by-caregivers-long-term-care
The number of gout patients is rising, with an estimated 8.3 million American adults diagnosed with gout—but only 10 percent of them are being properly treated, according to the Gout & Uric Acid Education Society. To heighten awareness and knowledge about gout and to lead to earlier diagnosis and treatment, the society has released two new comprehensive kits to educate patients and provide consistent information for medical professionals. The release of the Take a Stand on Gout Patient Education Kit and Medical Professional Information Kit coincides with Gout Awareness Day, an annual commemoration on May 22 to call attention to the growing incidence of gout and to enhance knowledge so as to improve patient outcomes. Both kits provide new, substantial information about gout from specialists, who treat gout patients every day.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61805-gout-uric-acid-education-society-take-a-stand-on-gout-new-information-kits
The Gout & Uric Acid Education Society (GUAES) has added six new educational videos for patients and medical professionals to its library of popular educational videos on gout, highlighting the society’s most important takeaways from the recently released American College of Rheumatology (ACR) Guidelines on Gout Diagnosis and Treatment. Available under the patient and medical professional portals on www.GoutEducation.org, respectively, the latest videos emphasize the need for continuous communication between gout patients and their doctors about their unique treatment plan, to help prevent gout flares and long-term complications from this poorly understood form of inflammatory arthritis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60699-gout-uric-acid-education-society-guaes-new-videos-on-acr-guidelines
Dune Medical Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify
